There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Jazz Pharmaceuticals (JAZZ) and AnaptysBio Inc (ANAB) with bullish sentiments.
Jazz Pharmaceuticals (JAZZ)
Cantor Fitzgerald analyst Brandon Folkes reiterated a Buy rating on Jazz Pharmaceuticals today and set a price target of $185. The company’s shares opened today at $128.65.
Folkes commented:
“: Post 1Q19, we reiterate our Overweight rating and 12- mo. PT of $185 on JAZZ shares. Jazz continues to grow its core sleep franchise and has been able to successfully build a pipeline in sleep and hemo/oncology to follow its Xyrem success. We believe that the sleep franchise durability remains underappreciated, driven by JZP-258 and Sunosi, and that the company has an interesting hemo/oncology business that could drive the next leg of growth and evolution for JAZZ. We believe that data readouts, launches and subsequent upwards earnings revisions, in both segments of the business, will drive upside to JAZZ’s current share price.”
According to TipRanks.com, Folkes is a 1-star analyst with an average return of -0.9% and a 32.4% success rate. Folkes covers the Healthcare sector, focusing on stocks such as Opiant Pharmaceuticals Inc, Eagle Pharmaceuticals Inc, and Collegium Pharmaceutical.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Jazz Pharmaceuticals with a $172.25 average price target.
See today’s analyst top recommended stocks >>
AnaptysBio Inc (ANAB)
In a report released today, Eliana Merle from Cantor Fitzgerald maintained a Buy rating on AnaptysBio Inc, with a price target of $140. The company’s shares opened today at $72.29.
Merle noted:
“AnaptysBio is a clinical stage, platform company with multiple clinical stage assets. Its lead asset, etokimab (ANB-020), is being studied for many allergic conditions. Among ANAB’s assets, etokimab is furthest ahead in atopic dermatitis, for which there were early-stage data in October 2017 that sent the shares up by 100%. We think there is meaningful de-risking left for etokimab, and we see multiple clinical catalysts in the next 18 months as key value drivers. Additional clinical assets, notably ANB-019, add key pieces of diversification, with initial readouts expected in 2019 that we believe are underappreciated.”
According to TipRanks.com, Merle has 0 stars on 0-5 star ranking scale with an average return of -9.4% and a 39.4% success rate. Merle covers the Healthcare sector, focusing on stocks such as BioMarin Pharmaceutical Inc., Aerpio Pharmaceuticals Inc, and Ionis Pharmaceuticals Inc.
AnaptysBio Inc has an analyst consensus of Strong Buy, with a price target consensus of $131.25.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
